Joint ACS–CRUK funding opportunity to drive translational primary prevention research grounded in biological and mechanistic understanding of cancer aetiology and risk, aiming to deliver precision prevention interventions through true UK–US scientific partnerships.
Eligibility Criteria:
-
Applicants may be at any career stage.
-
At least one independent investigator (full-time faculty or equivalent) at an eligible US institution and at least one at an eligible UK institution.
-
Proposals must represent a genuine, balanced UK–US collaboration with complementary expertise; include the rationale for the partnership, roles for all investigators, and planned synergies.
-
Evidence of prior collaboration is helpful; new teams should demonstrate cross-disciplinary synergy and translational potential.
Funding Details:
-
Cost-share model: CRUK funds admissible UK research costs up to GBP 600,000; ACS funds US-based research costs up to USD 860,000 plus 10% indirect costs (maximum USD 946,000).
-
Duration: 1–5 years.
-
Process: UK PI applies via CRUK Flexi-Grant (private link provided after remit confirmation). US PI submits the US budget in ProposalCentral; ACS must approve the US budget before the full CRUK application is submitted.
Deadline:
-
ACS budget submission: November 24, 2025.
-
Full application deadline (CRUK submission by UK PI): December 4, 2025.
-
Review: May 2026.
-
Anticipated award start: July 2026.
Where to go for further information:
-
Inquiries: [email protected] (ACS) and [email protected] (CRUK).